Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Jul. 31, 2018	Jul. 31, 2017
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (8,851,564)	$ (3,223,171)
Stock option compensation to employees and directors	3,598,986	932,773
Stock option compensation to consultants	197,040
Common stock award issued to employee pursuant to stock incentive plan	1,373,940
Warrants issued to consultant	57,050
Common stock issued to consultants	15,002	17,811
Depreciation of property and equipment	12,414	32,096
Amortization of patents	243,972	243,973
Accretion of interest on patent acquisition obligations to interest expense		228,026
Accrued interest on secured debenture		20,667
Gain on extinguishment of patent acquisition obligation		(1,547,608)
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee	64,656
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(203,921)	(199,254)
Accounts payable	(60,914)	92,191
Accrued expenses	300,888	345,074
Net cash used in operating activities	(3,252,451)	(3,057,422)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(4,000,000)	(4,251,000)
Proceeds from maturities of short-term investments in certificates of deposit	4,750,000	750,000
Purchase of property and equipment	(31,853)	(16,885)
Net cash provided by (used in) investing activities	718,147	(3,517,885)
Cash flows from financing activities:
Redemption of convertible preferred stock		(500,000)
Payments made on secured debenture		(1,000,000)
Proceeds from sale of common stock through a rights offering to shareholders		4,203,302
Proceeds from sale of common stock through a public offering		3,211,785
Proceeds from sale of common stock in at-the-market offering	1,786,029
Proceeds from exercise of employee stock options		5,665
Net cash provided by financing activities	1,786,029	5,920,752
Net decrease in cash and cash equivalents	(748,275)	(654,555)
Cash and cash equivalents at beginning of period	3,339,374	2,488,323
Cash and cash equivalents at end of period	2,591,099	1,833,768
Supplemental disclosure of non-cash financing and investing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 7)		(3,000,000)
Common stock issued to pay patent acquisition obligation (Note 6)		(2,852,294)
Issuance of non-controlling interest in Certainty Therapeutics, Inc	$ 64,656